Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
44 hedge funds and large institutions have $15.6M invested in Aevi Genomic Medicine Inc in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
10% more funds holding
Funds holding: 40 → 44 (+4)
10% more capital invested
Capital invested by funds: $14.2M → $15.6M (+$1.41M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$250K |
| 2 |
Millennium Management
New York
|
+$67.3K |
| 3 |
AMCA
Arthur M. Cohen & Associates
Northbrook,
Illinois
|
+$35.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$18.8K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$307K |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$117K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$93.8K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$19.1K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$14K |
GNMX Hedge Fund Activity: Q3 2018 in Review
44 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q3 2018, worth a combined $15.6M — up 9.9% from $14.2M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new GNMX positions and 3 closed out — a net gain of 4 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $250K. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $307K sold.
- 44 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q3 2018, up from 40 in Q2 2018.
- Funds reported $15.6M of Aevi Genomic Medicine Inc stock for Q3 2018, up 9.9% quarter-over-quarter.
- 7 funds opened new Aevi Genomic Medicine Inc positions in Q3 2018 and 3 closed out, a net change of +4 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q3 2018 was Bridgeway Capital Management, an estimated $250K added.
- The largest Aevi Genomic Medicine Inc seller in Q3 2018 was T. Rowe Price Associates, an estimated $307K sold.
Based on aggregated 13F filings for Q3 2018.